Today: 20 May 2026
Lululemon stock rises as founder Chip Wilson launches board proxy fight — what investors watch next
30 December 2025
1 min read

Lululemon stock rises as founder Chip Wilson launches board proxy fight — what investors watch next

NEW YORK, December 30, 2025, 01:23 ET — Market closed

  • Lululemon shares closed up 1.7% on Monday.
  • Founder Chip Wilson submitted director nominations ahead of the 2026 annual meeting.
  • CEO succession and proxy filings are the next near-term catalysts.

Lululemon Athletica Inc (LULU) shares closed up 1.7% on Monday at $212.54 after the company said founder Chip Wilson submitted nominations for three director candidates in a move that could trigger a proxy fight.

The board challenge lands in the middle of a leadership handoff. A regulatory filing showed CEO Calvin McDonald will step down effective Jan. 31, with finance chief Meghan Frank and chief commercial officer André Maestrini set to serve as interim co-CEOs while the company searches for a permanent replacement.

Founder pressure is arriving as the retailer tries to regain momentum after a bruising year. Lululemon shares are down about 45% in 2025 and the company is facing fast-growing rivals such as Alo Yoga and Vuori, Reuters reported. Morningstar analyst David Swartz said: “Adding three new board members seems like something that Lululemon would be willing to do.” Reuters

Wilson nominated former On Running co-CEO Marc Maurer, former ESPN chief marketing officer Laura Gentile and former Activision CEO Eric Hirshberg as independent director candidates, according to the report.

Wilson said the board’s handling of the CEO change was “the third total failure of board oversight,” arguing it lacked a clear succession plan and enough product experience.

Lululemon said it had engaged with Wilson “extensively and in good faith” and would evaluate the nominees under its governance process. It told shareholders they were not required to take any action now.

The company also said it intends to file proxy materials, including a proxy statement on Schedule 14A, ahead of the 2026 annual meeting. A proxy statement is the document companies file to solicit shareholder votes.

Elliott Management, which disclosed a $1 billion stake earlier this month, has also pushed for changes, Reuters reported, including backing former Ralph Lauren executive Jane Nielsen as a potential CEO candidate. A person familiar with Wilson’s thinking told Reuters he is not working with other investors.

For investors, the near-term question is whether the board fight speeds up a CEO decision or prolongs uncertainty over strategy and product direction. Proxy contests can be costly and distracting, especially when management is already in transition.

Before the next session, attention will turn to any new SEC filings that clarify the nominees’ case and the board’s formal recommendation, and the timetable for a shareholder vote.

The Jan. 31 leadership transition is another key date. Investors will be watching for updates on how Frank and Maestrini plan to steady the business once they take over on an interim basis.

Lululemon has not yet posted a next earnings date on its investor-events calendar, leaving the CEO search and proxy process as the clearest upcoming drivers for the stock.

Stock Market Today

  • Goldman Sachs Sees North Asian Stocks Outperforming Southern Markets on AI and Energy Resilience
    May 19, 2026, 9:30 PM EDT. According to Goldman Sachs strategist Tim Moe, North Asian equity markets outperform South Asian ones due to greater resilience to energy shocks and strong AI sector growth. South Korea and Taiwan lead with tech-heavy indices, posting significant year-to-date gains, including over 80% in South Korea. In contrast, South Asia, including Indonesia, suffers a 25% decline due to lacking technology exposure and higher energy vulnerability. China's A-shares have gained 10% amid emerging deflation recovery and policy support, while H-shares lag given weaker tech earnings. Moe warns of potential market corrections as energy supply shocks loom, despite optimism for stable Japanese markets fueled by political stability and AI robotics growth.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 30.12.2025

Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision
Next Story

Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Go toTop